NCT05392569

Brief Summary

Deep brain stimulation (DBS) has been approved for treatment of dystonia by the FDA under a humanitarian device exemption (HDE) status. DBS has been shown to be very effective in the treatment of a variety of diseases such as Parkinson's disease and essential tremor. It has been widely used for the treatment of primary and secondary dystonia as well. Surgery involves the placement of the DBS electrode in one or two of the deep nuclei constituting the basal ganglia. A subcutaneous thoracic or abdominal implantable pulse generator is placed and connected to the intracranial electrode. Pulsatile stimulation of the deep brain nuclei has been shown to result in significant improvement in many patients, including restoration of the ability to walk or make voluntary arm movements. A major difficulty with DBS is the accurate placement of the electrode. Adult patients are usually awakened during surgery and micro electrode recordings are used to determine the optimal electrode effectiveness and monitor for side effects. This requires the patient to be awake and cooperate, while on the operating table. When DBS is performed in children, such testing is often not possible because the children are scared or not cooperative when awakened during surgery, the procedure is most often done for Dystonia, which does not respond immediately, and dystonia may cause involuntary movements that could be dangerous in the operating room while the child's brain is exposed. As part of the routine clinical evaluation of target location in the operating room or Neuromodulation Unit, stimulation is performed using the deep brain or depth electrodes, typically at frequencies between 60hz and 185hz. For this research study, stimulation will occur at much lower frequencies, between 9hz and 20hz in order to be able to measure how electrical activity from the deep electrodes spreads to other electrodes or the scalp. As part of the research, peripheral nerves will also be stimulated at the wrist and knee at frequencies of 20hz to 150hz in order to measure the transmission of peripheral nerve stimulation to these areas of the brain. The investigators hope these additional studies will allow discovery for mechanisms that lead to movement disorders including dystonia, and that knowledge of these mechanisms will allow the investigators to develop new, safer, and more effective treatments in the future.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2013

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 13, 2013

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2021

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

May 18, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 26, 2022

Completed
Last Updated

May 26, 2022

Status Verified

May 1, 2022

Enrollment Period

5.9 years

First QC Date

May 18, 2022

Last Update Submit

May 24, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of Change in Dystonia using the Barry Albright Dystonia Scale

    The Barry-Albright Dystonia Scale (BADS) is the most common outcome measure reported in intervention studies for children with dyskinetic cerebral palsy. Dystonia severity is rated on a 5-point (0 - 4), criterion based, ordinal scale for eight body regions (eyes, mouth, neck, trunk, left/right upper extremities and left/right lower extremities. The minimum score value is 0 (least severe) and the maximum score value is 32 (most severe).

    1,3,6,12 months

Interventions

In addition to standard micro electrode recordings, we propose to measure: 1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site 2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves 3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves 4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site.

Eligibility Criteria

Age5 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Has plans to be implanted with a deep brain stimulator device. Although Medtronic's product information indicate that DBS is for individuals 7 years of age and older some DBS centers such as UCSF have implanted kids younger for off-label use. By including children 5 years of age into our study, we do not exclude children that may receive DBS off-label.

You may qualify if:

  • \- Subjects 5 years of age and/or older (including adults, ages 18+)
  • Has chronic, intractable (drug refractory), generalized dystonia
  • DBS surgery must be clinically indicated

You may not qualify if:

  • Contraindication to neurosurgery and or a potentially reversible cause of dystonia that does not include surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hernandez-Martin E, Arguelles E, Zheng Y, Deshpande R, Sanger TD. High-fidelity transmission of high-frequency burst stimuli from peripheral nerve to thalamic nuclei in children with dystonia. Sci Rep. 2021 Apr 19;11(1):8498. doi: 10.1038/s41598-021-88114-w.

    PMID: 33875779BACKGROUND

MeSH Terms

Interventions

Deep Brain Stimulation

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Provost Associate Professor

Study Record Dates

First Submitted

May 18, 2022

First Posted

May 26, 2022

Study Start

November 13, 2013

Primary Completion

October 1, 2019

Study Completion

November 2, 2021

Last Updated

May 26, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share